Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Stephen Chia"'
Autor:
Daegan Sit, Nafisha Lalani, Elisa Chan, Eric Tran, Caroline Speers, Lovedeep Gondara, Stephen Chia, Karen Gelmon, Caroline Lohrisch, Alan Nichol
Publikováno v:
Radiotherapy and Oncology. 174:S6
Autor:
Yussanne Ma, Diana N. Ionescu, Daniel J. Renouf, Marco A. Marra, Erin Pleasance, Cheryl Ho, Richard A. Moore, E. Zhong, David F. Schaeffer, Sreeja Leelakumari, Yongjun Zhao, Martin Jones, Caralyn Reisle, C. Zhao, Julie Ho, Karen Mungall, Andrew J. Mungall, Stephen Yip, Karen A. Gelmon, Tony Ng, Janessa Laskin, Stephen Chia, Steven J.M. Jones, Howard John Lim, Yaoqing Shen, Carolyn Ch'ng
Publikováno v:
Annals of Oncology. 28:3092-3097
Background NRG1 fusion-positive lung cancers have emerged as potentially actionable events in lung cancer, but clinical support is currently limited and no evidence of efficacy of this approach in cancers beyond lung has been shown. Patients and meth
Autor:
Gabe S. Sonke, Agnes Lteif, Sara A. Hurvitz, G. Jerusalem, Y-S Lu, S-A. Im, S. Campos, H. Hu, Stephen Chia, Yirong Wang, Karen Rodriguez-Lorenc, S.C. Lee
Publikováno v:
Annals of Oncology. 31:S376-S377
Autor:
Stephen Chia, Sara A. Hurvitz, Eva Ciruelos, G. Jerusalem, X. C. Hu, Mario E. Lacouture, S-A. Im, Hope S. Rugo, Farhat Ghaznawi, Yoon Sim Yap, Faye Su, Ruth O'Regan, Y. Han, Wolfgang Janni, Sarat Chandarlapaty
Publikováno v:
Annals of Oncology. 31:S389-S390
Autor:
M. Mates, Stephen Chia, John Hilton, S. R. Kulkarni, J-W. Henning, C. Doyle, S. Haftchenary, Sabrina R. Perri, Nayyer Iqbal, Nathaniel Bouganim, Theodore A. Vandenberg, Nadia Califaretti, Cristiano Ferrario
Publikováno v:
Annals of Oncology. 31:S374-S375
Autor:
Juan Pablo Zarate, J. Wu, Sabrina R. Perri, R.A. Leite, Stephen Chia, Anil A. Joy, L. Menon-Singh, Ellen Warner, Cristiano Ferrario, S. Haftchenary, Nadia Califaretti, Susan Dent
Publikováno v:
Annals of Oncology. 31:S369-S370
Autor:
Dejan Juric, Thomas Bachelot, Hope S. Rugo, Nickolas Sophos, Jonathan Polikoff, Antonia Ridolfi, Stephen Chia, Eva Ciruelos, M. Ruiz Borrego, N. Turner, B. Cooper, A. Thuerigen, Florence Lerebours
Publikováno v:
Annals of Oncology. 30:v141
Background Approximately 40% of pts with HR+, HER2– ABC have mutations (mut) in PIK3CA, which encodes α-PI3K and leads to PI3K pathway hyperactivation and potentially ET resistance. ALP is a selective inhibitor of α-PI3K that, in combination with
Autor:
J. Wu, Sabrina R. Perri, Anil A. Joy, S. Haftchenary, Nadia Califaretti, Ellen Warner, Susan Dent, Cristiano Ferrario, M. Lakshmi, Stephen Chia, Juan Pablo Zarate
Publikováno v:
Annals of Oncology. 30:v120
Background CDK4/6 inhibitor Ribociclib (RIBO) was approved by Health Canada in combination with letrozole (LET) for the treatment of HR+, HER2– advanced breast cancer (ABC) in postmenopausal women with no prior therapy for advanced disease. This wa
Autor:
A. Chan, Antonia Ridolfi, S.-A. Im, Stephen Chia, Gabriel N. Hortobagyi, DJ Slamon, Francisco J. Esteva, Denise A. Yardley, Sara A Hurvitz, Debu Tripathy
Publikováno v:
Annals of Oncology. 30:iii49-iii50
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 28(12)
Background Novel immune checkpoint blockade strategies are being evaluated in clinical trials and include targeting the lymphocyte activation gene 3 (LAG-3) checkpoint, alone or in combination with PD-1/PD-L1 blockade. We investigated LAG-3 expressio